Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
Apply
Decitabine/Cedazuridine
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step